Jaguar Health's 15min chart shows MACD Death Cross and Bearish Marubozu.

Jaguar Health's 15-minute chart exhibits a significant technical indicator, a MACD Death Cross, which occurred on May 16, 2025 at 15:15. This bearish event signifies a potential continuation of the downward trend in the stock price, with sellers dominating the market and a strong likelihood of sustained bearish momentum.

Jaguar Health Inc. (NASDAQ: JAGX) reported its Q1 2025 earnings on May 15, 2025, with a mixed bag of results. The company's net revenue decreased by approximately 6% year-over-year (YoY) to $2.2 million, marking a significant drop from the previous quarter's $2.4 million [1]. The loss from operations increased to $9.4 million, up from $8.2 million in the same period last year, indicating rising operational costs [2].

Despite the financial challenges, Jaguar Health highlighted several positive developments. The company reported an increase in dispensed prescriptions for Mytesi, its flagship product, by approximately 2% in Q1 2025 compared to Q1 2024 [1]. Additionally, initial proof-of-concept results for crofelemer, a novel liquid formulation, showed a reduction in total parenteral nutrition (TPN) by up to 27% in MVID patients and 12.5% in pediatric short bowel syndrome (SBS) patients [1]. These results could lead to expedited regulatory approval pathways for both conditions.

The OnTarget Phase III clinical trial for crofelemer, while not achieving statistical significance overall, showed significant results in a prespecified subgroup of adult breast cancer patients. This led to a Type C meeting with the FDA to discuss regulatory pathways for cancer therapy-related diarrhea [1]. Jaguar Health is also engaged in multiple ongoing trials for MVID and SBS, with results expected in the first half of 2026 [1].

The company's stock experienced a notable decline, closing down 10.86% at $6.17 on May 16, 2025, following the earnings release. The stock is currently trading near its 52-week low of $4.02, with a dramatic 98.39% decline over the past year [2]. Jaguar Health's market capitalization is now just $3.69 million, and the company has a significant debt burden, which is quickly burning through its cash reserves [2].

Looking ahead, Jaguar Health is focusing on advancing its pipeline of treatments for rare diseases and pursuing business development opportunities to support its strategic goals. The company is also exploring non-dilutive funding through partnerships and licensing deals [1].

References:
[1] https://finance.yahoo.com/news/jaguar-health-inc-jagx-q1-071208066.html
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-jaguar-health-reports-q1-2025-with-stock-drop-93CH-4049284